U.S. Influenza Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

U.S. Influenza Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

“The U.S. Influenza Market is anticipated to reach about US$ XX Mn by 2025, and anticipated to expand at a CAGR over seven years of forecast period 2019-2025” owing to increased vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities.

Precision Business Insights (PBI) in its report titled “U.S. Influenza Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The U.S. Influenza market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$ XX Mn by 2025. Increased geriatric population and new born babies will create demand for U.S. influenza market.

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/#ulp-h4n2eZVGqb32xpPc

U.S. influenza market is segmented on the basis of product type, distribution channel, and end user.

Launch of New Products Expected to Fuel the Growth of U.S. Influenza Market

The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market.

U.S. Projected to Dominate the Revenue Share in Global Influenza Market

U.S. is expected to dominate the revenue share owing to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence of influenza might increase the growth of U.S. influenza market. Similarly, the upsurge in funding by the government is expected to drive the market growth in the United States.

Strategic Collaborations Expected to Fuel the U.S. Influenza Market

In November 2016, GSK received approval from U.S. Food and Drug Administration for ‘Flulaval’ Quadrivalent to include use in children aged six months or older. In May 2016, Seqirus received approval from U.S. Food and Drug Administration for ‘Flucelvax’, Quadrivalent that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older.

Some of the players in U.S. influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc (U.S.)., Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.

Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/#ulp-4H8Z4LpNMLEuOnnx

Detailed Segmentation

By Drug Class Type

o Anti-viral drugs
• Zanamivir
• Oseltamivir
• Amantadine
• Rimantadine
• Others
• Interferons
o Vaccines
• Trivalent
• Quadrivalent

By Route of Administration

o Oral
o Parenteral
o Others

By Distribution Channel

o Hospital pharmacies
o Retail pharmacies
o Others

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ www.precisionbusinessinsights.com

This release was published on openPR.